Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 149-174

  Gencel, V B ^a   Benjamin, M M ^a   Bahou, S N ^a   Khalil, R A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood pressure; Calcium; Endothelium; Estrogen; Smooth muscle

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANTIOXIDANT; CYCLIC AMP; CYCLIC GMP; DAIDZEIN; DAIDZIN; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GENISTEIN; IDRONOXIL; ISOFLAVONE; LIGNAN; MITOGEN ACTIVATED PROTEIN KINASE; PHYTOESTROGEN; POTASSIUM CHANNEL; PROSTACYCLIN; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; RESVERATROL; RHO KINASE; UNINDEXED DRUG;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DATA BASE; DIETARY INTAKE; DISEASE COURSE; DRUG CLASSIFICATION; DRUG METABOLISM; DRUG STRUCTURE; ENDOTHELIUM CELL; EXPERIMENTAL STUDY; EXTRACELLULAR MATRIX; FOLLOW UP; HORMONAL THERAPY; HUMAN; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; MORTALITY; NONHUMAN; SOYBEAN; THROMBOCYTE AGGREGATION; TISSUE INJURY; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASCULITIS;

ANIMALS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MUSCLE, SMOOTH, VASCULAR; PHYTOESTROGENS;

EID: 84856496494     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712798995020     Document Type: Article

References (246)

1. Hays, J.; Ockene, J.K.; Brunner, R.L.; Kotchen, J.M.; Manson, J.E.; Patterson, R.E.; Aragaki, A.K.; Shumaker, S.A.; Brzyski, R.G.; LaCroix, A.Z.; Granek, I.A.; Valanis, B.G. Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med., 2003, 348(19), 1839-1854.
2. Stefanick, M.L. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am. J. Med., 2005, 118 Suppl 12B, 64-73.
3. Smiley, D.A.; Khalil, R.A. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr. Med. Chem., 2009, 16(15), 1863-1887.
4. Dubey, R.K.; Imthurn, B.; Zacharia, L.C.; Jackson, E.K. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension, 2004, 44(6), 789-795.
5. Ross, R.L.; Serock, M.R.; Khalil, R.A. Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease. Curr. Cardiol. Rev., 2008, 4(4), 309-322.
6. Orshal, J.M.; Khalil, R.A. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 286(2), R233-249.
7. Crews, J.K.; Murphy, J.G.; Khalil, R.A. Gender differences in Ca(2+) entry mechanisms of vasoconstriction in Wistar-Kyoto and spontaneously hypertensive rats. Hypertension, 1999, 34(4 Pt 2), 931-936.
8. Mendelsohn, M.E. Genomic and nongenomic effects of estrogen in the vasculature. Am. J. Cardiol., 2002, 90(1A), 3F-6F.
9. Grodstein, F.; Stampfer, M.J.; Manson, J.E.; Colditz, G.A.; Willett, W.C.; Rosner, B.; Speizer, F.E.; Hennekens, C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med., 1996, 335(7), 453-461.
10. Stampfer, M.J.; Colditz, G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med., 1991, 20(1), 47-63.
11. Manson, J.E.; Hsia, J.; Johnson, K.C.; Rossouw, J.E.; Assaf, A.R.; Lasser, N.L.; Trevisan, M.; Black, H.R.; Heckbert, S.R.; Detrano, R.; Strickland, O.L.; Wong, N.D.; Crouse, J.R.; Stein, E.; Cushman, M. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med., 2003, 349(6), 523-534.
12. Glazier, M.G.; Bowman, M.A. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch. Intern. Med., 2001, 161(9), 1161-1172.
13. Salari Sharif, P.; Nikfar, S.; Abdollahi, M. Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis. Age (Dordr).
14. Lund, T.D.; Munson, D.J.; Adlercreutz, H.; Handa, R.J.; Lephart, E.D. Androgen receptor expression in the rat prostate is downregulated by dietary phytoestrogens. Reprod. Biol. Endocrinol., 2004, 2, 5.
15. Messina, M.J.; Persky, V.; Setchell, K.D.; Barnes, S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer., 1994, 21(2), 113-131.
16. Zhao, L.; Mao, Z.; Brinton, R.D. A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology, 2009, 150(2), 770-783.
17. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; Le Cornu, K.A.; Ryder, J.J.; Hall, W.L.; Cassidy, A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr., 2008, 88(1), 38-50.
18. Adlercreutz, H.; Mazur, W. Phyto-oestrogens and Western diseases. Ann. Med., 1997, 29(2), 95-120.
19. Yamori, Y. Food factors for atherosclerosis prevention: Asian perspective derived from analyses of worldwide dietary biomarkers. Exp. Clin. Cardiol., 2006, 11(2), 94-98.
20. Kurzer, M.S. Phytoestrogen supplement use by women. J. Nutr., 2003, 133(6), 1983S-1986S.
21. Pilsakova, L.; Riecansky, I.; Jagla, F. The physiological actions of isoflavone phytoestrogens. Physiol Res.
22. Thompson, L.U.; Boucher, B.A.; Liu, Z.; Cotterchio, M.; Kreiger, N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr. Cancer, 2006, 54(2), 184-201.
23. Glitso, L.V.; Mazur, W.M.; Adlercreutz, H.; Wahala, K.; Makela, T.; Sandstrom, B.; Bach Knudsen, K.E. Intestinal metabolism of rye lignans in pigs. Br. J. Nutr., 2000, 84(4), 429-437.
24. Schmitt, E.; Lehmann, L.; Metzler, M.; Stopper, H. Hormonal and genotoxic activity of resveratrol. Toxicol. Lett., 2002, 136(2), 133-142.
25. D'Alessandro, T.L.; Boersma-Maland, B.J.; Peterson, T.G.; Sfakianos, J.; Prasain, J.K.; Patel, R.P.; Darley-Usmar, V.M.; Botting, N.P.; Barnes, S. Metabolism of phytoestrogen conjugates. Methods Enzymol., 2005, 400, 316-342.
26. Setchell, K.D.; Brown, N.M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B.E.; Brashear, W.T.; Kirschner, A.S.; Cassidy, A.; Heubi, J.E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr., 2001, 131(4 Suppl), 1362S-1375S.
27. King, R.A.; Bursill, D.B. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am. J. Clin. Nutr., 1998, 67(5), 867-872.
28. Adlercreutz, H.; Markkanen, H.; Watanabe, S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet, 1993, 342(8881), 1209-1210.
29. Setchell, K.D. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr., 1998, 68(6 Suppl), 1333S-1346S.
30. Setchell, K.D.; Brown, N.M.; Lydeking-Olsen, E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr., 2002, 132(12), 3577-3584.
31. Duncan, A.M.; Merz-Demlow, B.E.; Xu, X.; Phipps, W.R.; Kurzer, M.S. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., 2000, 9(6), 581-586.
32. Kurzer, M.S.; Xu, X. Dietary phytoestrogens. Annu Rev Nutr, 1997, 17, 353-381.
33. Faughnan, M.S.; Hawdon, A.; Ah-Singh, E.; Brown, J.; Millward, D.J.; Cassidy, A. Urinary isoflavone kinetics: the effect of age, gender, food matrix and chemical composition. Br. J. Nutr., 2004, 91(4), 567-574.
34. Setchell, K.D.; Cole, S.J. Variations in isoflavone levels in soy foods and soy protein isolates and issues related to isoflavone databases and food labeling. J. Agric. Food Chem., 2003, 51(14), 4146-4155.
35. Morito, K.; Hirose, T.; Kinjo, J.; Hirakawa, T.; Okawa, M.; Nohara, T.; Ogawa, S.; Inoue, S.; Muramatsu, M.; Masamune, Y. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol. Pharm. Bull., 2001, 24(4), 351-356.
36. Zhou, J.; Cidlowski, J.A. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids, 2005, 70(5-7), 407-417.
37. Kuiper, G.G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 1997, 138(3), 863-870.
38. Hall, J.M.; Korach, K.S. Analysis of the molecular mechanisms of human estrogen receptors alpha and beta reveals differential specificity in target promoter regulation by xenoestrogens. J. Biol. Chem., 2002, 277(46), 44455-44461.
39. Razandi, M.; Pedram, A.; Greene, G.L.; Levin, E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol., 1999, 13(2), 307-319.
40. Ascenzi, P.; Bocedi, A.; Marino, M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med., 2006, 27(4), 299-402.
41. Miller, V.M.; Duckles, S.P. Vascular actions of estrogens: functional implications. Pharmacol Rev, 2008, 60(2), 210-241.
42. Chambliss, K.L.; Yuhanna, I.S.; Anderson, R.G.; Mendelsohn, M.E.; Shaul, P.W. ERbeta has nongenomic action in caveolae. Mol. Endocrinol., 2002, 16(5), 938-946.
43. Prossnitz, E.R.; Arterburn, J.B.; Smith, H.O.; Oprea, T.I.; Sklar, L.A.; Hathaway, H.J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Ann. Rev. Physiol., 2008, 70, 165-190.
44. Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307(5715), 1625-1630.
45. Filardo, E.; Quinn, J.; Pang, Y.; Graeber, C.; Shaw, S.; Dong, J.; Thomas, P. Activation of the novel estrogen receptor G proteincoupled receptor 30 (GPR30) at the plasma membrane. Endocrinology, 2007, 148(7), 3236-3245.
46. Osterlund, M.; Kuiper, G.G.; Gustafsson, J.A.; Hurd, Y.L. Differential distribution and regulation of estrogen receptor-alpha and-beta mRNA within the female rat brain. Brain Res. Mol. Brain Res., 1998, 54(1), 175-180.
47. Fang, H.; Tong, W.; Shi, L.M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B.S.; Xie, Q.; Dial, S.L.; Moland, C.L.; Sheehan, D.M. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem. Res. Toxicol., 2001, 14(3), 280-294.
48. Zhu, B.T.; Han, G.Z.; Shim, J.Y.; Wen, Y.; Jiang, X.R. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology, 2006, 147(9), 4132-4150.
49. Couse, J.F.; Korach, K.S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev., 1999, 20(3), 358-417.
50. Hall, J.M.; McDonnell, D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology, 1999, 140(12), 5566-5578.
51. Bjornstrom, L.; Sjoberg, M. Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl. Recept, 2004, 2(1), 3.
52. Ignar-Trowbridge, D.M.; Nelson, K.G.; Bidwell, M.C.; Curtis, S.W.; Washburn, T.F.; McLachlan, J.A.; Korach, K.S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA, 1992, 89(10), 4658-4662.
53. Filardo, E.J.; Thomas, P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab., 2005, 16(8), 362-367.
54. Kousteni, S.; Bellido, T.; Plotkin, L.I.; O'Brien, C.A.; Bodenner, D.L.; Han, L.; Han, K.; DiGregorio, G.B.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S.; Roberson, P.K.; Weinstein, R.S.; Jilka, R.L.; Manolagas, S.C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell, 2001, 104(5), 719-730.
55. Oviedo, P.J.; Sobrino, A.; Laguna-Fernandez, A.; Novella, S.; Tarin, J.J.; Garcia-Perez, M.A.; Sanchis, J.; Cano, A.; Hermenegildo, C. Estradiol induces endothelial cell migration and proliferation through estrogen receptor-enhanced RhoA/ROCK pathway. Mol. Cell Endocrinol.
56. Cho, M.M.; Ziats, N.P.; Pal, D.; Utian, W.H.; Gorodeski, G.I. Estrogen modulates paracellular permeability of human endothelial cells by eNOS-and iNOS-related mechanisms. Am. J. Physiol., 1999, 276(2 Pt 1), C337-349.
57. Cipolla, M.J.; Godfrey, J.A.; Wiegman, M.J. The effect of ovariectomy and estrogen on penetrating brain arterioles and bloodbrain barrier permeability. Microcirculation, 2009, 16(8), 685-693.
58. Hass, M.A.; Nichol, P.; Lee, L.; Levin, R.M. Estrogen modulates permeability and prostaglandin levels in the rabbit urinary bladder. Prostaglandins. Leukot. Essent. Fatty Acids, 2009, 80(2-3), 125-129.
59. Sandoval, M.J.; Cutini, P.H.; Rauschemberger, M.B.; Massheimer, V.L. The soyabean isoflavone genistein modulates endothelial cell behaviour. Br. J. Nutr., 104(2), 171-179.
60. Fu, X.H.; Wang, L.; Zhao, H.; Xiang, H.L.; Cao, J.G. Synthesis of genistein derivatives and determination of their protective effects against vascular endothelial cell damages caused by hydrogen peroxide. Bioorg. Med. Chem. Lett., 2008, 18(2), 513-517.
61. Si, H.; Liu, D. Isoflavone genistein protects human vascular endothelial cells against tumor necrosis factor-alpha-induced apoptosis through the p38beta mitogen-activated protein kinase. Apoptosis., 2009, 14(1), 66-76.
62. Kamiyama, M.; Kishimoto, Y.; Tani, M.; Utsunomiya, K.; Kondo, K. Effects of equol on oxidized low-density lipoprotein-induced apoptosis in endothelial cells. J. Atheroscler. Thromb., 2009, 16(3), 239-249.
63. Cheng, C.; Wang, X.; Weakley, S.M.; Kougias, P.; Lin, P.H.; Yao, Q.; Chen, C. The soybean isoflavonoid equol blocks ritonavirinduced endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J. Nutr., 140(1), 12-17.
64. Ying, C.; Hsu, J.T.; Shieh, S.C. Growth inhibition of human endothelial cells by the phyto-oestrogen biochanin A, a metabolite of genistein. Br. J. Nutr., 2001, 85(5), 615-620.
65. Nakajima, M.; Cooney, M.J.; Tu, A.H.; Chang, K.Y.; Cao, J.; Ando, A.; An, G.J.; Melia, M.; de Juan, E., Jr. Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest. Ophthalmol. Vis. Sci., 2001, 42(9), 2110-2114.
66. Rubinstein, I. Bradykinin-and substance P-induced edema formation in the hamster cheek pouch is tyrosine kinase dependent. J. Appl. Physiol., 2007, 103(1), 184-189.
67. Fujii, E.; Irie, K.; Ohba, K.; Ogawa, A.; Yoshioka, T.; Yamakawa, M.; Muraki, T. Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin. Naunyn. Schmiedebergs Arch. Pharmacol., 1997, 356(4), 475-480.
68. Liu, D.; Jiang, H.; Grange, R.W. Genistein activates the 3',5'-cyclic adenosine monophosphate signaling pathway in vascular endothelial cells and protects endothelial barrier function. Endocrinology, 2005, 146(3), 1312-1320.
69. Kauser, K.; Rubanyi, G.M. Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension, 1995, 25(4 Pt 1), 517-523.
70. Christodoulakos, G.; Panoulis, C.; Kouskouni, E.; Chondros, C.; Dendrinos, S.; Creatsas, G. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecol. Endocrinol., 2002, 16(1), 9-17.
71. Hernandez, I.; Delgado, J.L.; Diaz, J.; Quesada, T.; Teruel, M.J.; Llanos, M.C.; Carbonell, L.F. 17beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(5), R1599-1605.
72. Si, H.; Liu, D. Phytochemical genistein in the regulation of vascular function: new insights. Curr. Med. Chem., 2007, 14(24), 2581-2589.
73. Rathel, T.R.; Leikert, J.F.; Vollmar, A.M.; Dirsch, V.M. The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide-synthase system in vitro. Br. J. Pharmacol., 2005, 144(3), 394-399.
74. Liu, D.; Homan, L.L.; Dillon, J.S. Genistein acutely stimulates nitric oxide synthesis in vascular endothelial cells by a cyclic adenosine 5'-monophosphate-dependent mechanism. Endocrinology, 2004, 145(12), 5532-5539.
75. Joy, S.; Siow, R.C.; Rowlands, D.J.; Becker, M.; Wyatt, A.W.; Aaronson, P.I.; Coen, C.W.; Kallo, I.; Jacob, R.; Mann, G.E. The isoflavone Equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J. Biol. Chem., 2006, 281(37), 27335-27345.
76. Siriviriyakul, P.; Khemapech, S.; Monsiri, K.; Patumraj, S. The vascular effect of genistein: what is its mechanism, nitric oxide or PGI2? Clin. Hemorheol. Microcirc., 2006, 34(1-2), 97-101.
77. Chanawirat, A.; Khemapech, S.; Patumraj, S.; Siriviriyakul, P. Genistein replacement therapy on endothelial dysfunction and bone loss in bilateral ovariectomized rats. Clin. Hemorheol. Microcirc., 2006, 34(1-2), 309-314.
78. Jackman, K.A.; Woodman, O.L.; Chrissobolis, S.; Sobey, C.G. Vasorelaxant and antioxidant activity of the isoflavone metabolite equol in carotid and cerebral arteries. Brain Res., 2007, 1141, 99-107.
79. Wu, J.H.; Li, Q.; Wu, M.Y.; Guo, D.J.; Chen, H.L.; Chen, S.L.; Seto, S.W.; Au, A.L.; Poon, C.C.; Leung, G.P.; Lee, S.M.; Kwan, Y.W.; Chan, S.W. Formononetin, an isoflavone, relaxes rat isolated aorta through endothelium-dependent and endotheliumindependent pathways. J. Nutr. Biochem., 21(7), 613-620.
80. Grossini, E.; Molinari, C.; Mary, D.A.; Uberti, F.; Caimmi, P.P.; Surico, N.; Vacca, G. Intracoronary genistein acutely increases coronary blood flow in anesthetized pigs through beta-adrenergic mediated nitric oxide release and estrogenic receptors. Endocrinology, 2008, 149(5), 2678-2687.
81. Chalopin, M.; Tesse, A.; Martinez, M.C.; Rognan, D.; Arnal, J.F.; Andriantsitohaina, R. Estrogen receptor alpha as a key target of red wine polyphenols action on the endothelium. PLoS One, 5(1), e8554.
82. Simoncini, T.; Fornari, L.; Mannella, P.; Caruso, A.; Garibaldi, S.; Baldacci, C.; Genazzani, A.R. Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause, 2005, 12(1), 69-77.
83. Woodman, O.L.; Boujaoude, M. Chronic treatment of male rats with daidzein and 17 beta-oestradiol induces the contribution of EDHF to endothelium-dependent relaxation. Br. J. Pharmacol., 2004, 141(2), 322-328.
84. Palmon, S.C.; Williams, M.J.; Littleton-Kearney, M.T.; Traystman, R.J.; Kosk-Kosicka, D.; Hurn, P.D. Estrogen increases cGMP in selected brain regions and in cerebral microvessels. J. Cereb. Blood Flow Metab., 1998, 18(11), 1248-1252.
85. Darkow, D.J.; Lu, L.; White, R.E. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am. J. Physiol., 1997, 272(6 Pt 2), H2765-2773.
86. El-Mowafy, A.M.; Alkhalaf, M.; Jaffal, S.M. Nongenomic activation of the GC-A enzyme by resveratrol and estradiol downstream from membrane estrogen receptors in human coronary arterial cells. Nutr. Metab. Cardiovasc. Dis., 2007, 17(7), 508-516.
87. Barber, D.A.; Miller, V.M. Gender differences in endotheliumdependent relaxations do not involve NO in porcine coronary arteries. Am. J. Physiol., 1997, 273(5 Pt 2), H2325-2332.
88. Egan, K.M.; Lawson, J.A.; Fries, S.; Koller, B.; Rader, D.J.; Smyth, E.M.; Fitzgerald, G.A. COX-2-derived prostacyclin confers atheroprotection on female mice. Science, 2004, 306(5703), 1954-1957.
89. Garcia-Martinez, M.C.; Hermenegildo, C.; Tarin, J.J.; Cano, A. Phytoestrogens increase the capacity of serum to stimulate prostacyclin release in human endothelial cells. Acta. Obstet. Gynecol. Scand., 2003, 82(8), 705-710.
90. Hermenegildo, C.; Oviedo, P.J.; Garcia-Perez, M.A.; Tarin, J.J.; Cano, A. Effects of phytoestrogens genistein and daidzein on prostacyclin production by human endothelial cells. J. Pharmacol. Exp. Ther., 2005, 315(2), 722-728.
91. Vera, R.; Galisteo, M.; Villar, I.C.; Sanchez, M.; Zarzuelo, A.; Perez-Vizcaino, F.; Duarte, J. Soy isoflavones improve endothelial function in spontaneously hypertensive rats in an estrogenindependent manner: role of nitric-oxide synthase, superoxide, and cyclooxygenase metabolites. J. Pharmacol. Exp. Ther., 2005, 314(3), 1300-1309.
92. Fukuyama, K.; Ichiki, T.; Ono, H.; Tokunou, T.; Iino, N.; Masuda, S.; Ohtsubo, H.; Takeshita, A. cAMP-response element-binding protein mediates prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2005, 338(2), 910-918.
93. Wang, X.; Klein, R.D. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol. Carcinog., 2007, 46(11), 912-923.
94. Shingo, A.S.; Kito, S. Estrogen induces elevation of cAMPdependent protein kinase activity in immortalized hippocampal neurons: imaging in living cells. J. Neural Transm., 2002, 109(2), 171-174.
95. Zhou, Y.; Watters, J.J.; Dorsa, D.M. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology, 1996, 137(5), 2163-2166.
96. Lee, M.Y.; Leung, S.W.; Vanhoutte, P.M.; Man, R.Y. Genistein reduces agonist-induced contractions of porcine coronary arterial smooth muscle in a cyclic AMP-dependent manner. Eur. J. Pharmacol., 2004, 503(1-3), 165-172.
97. Satake, N.; Imanishi, M.; Keto, Y.; Yamada, H.; Ishikawa, M.; Shibata, S. Genistein potentiates the relaxation induced by beta1-and beta2-adrenoceptor activation in rat aortic rings. J. Cardiovasc. Pharmacol., 2000, 35(2), 227-233.
98. Ng, W.W.; Keung, W.; Xu, Y.C.; Ng, K.F.; Leung, G.P.; Vanhoutte, P.M.; Choy, P.C.; Man, R.Y. Genistein potentiates protein kinase A activity in porcine coronary artery. Mol. Cell Biochem., 2008, 311(1-2), 37-44.
99. Busse, R.; Edwards, G.; Feletou, M.; Fleming, I.; Vanhoutte, P.M.; Weston, A.H. EDHF: bringing the concepts together. Trends Pharmacol. Sci., 2002, 23(8), 374-380.
100. Villar, I.C.; Hobbs, A.J.; Ahluwalia, A. Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor. J. Endocrinol., 2008, 197(3), 447-462.
101. Dhaun, N.; Pollock, D.M.; Goddard, J.; Webb, D.J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci., 2007, 28(11), 573-579.
102. Kirkby, N.S.; Hadoke, P.W.; Bagnall, A.J.; Webb, D.J. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br. J. Pharmacol., 2008, 153(6), 1105-1119.
103. Dubey, R.K.; Jackson, E.K.; Keller, P.J.; Imthurn, B.; Rosselli, M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension, 2001, 37(2 Part 2), 640-644.
104. Rodrigo, M.C.; Martin, D.S.; Eyster, K.M. Vascular ECE-1 mRNA expression decreases in response to estrogens. Life Sci, 2003, 73(23), 2973-2983.
105. Cross, J.C. The genetics of pre-eclampsia: a feto-placental or maternal problem? Clin. Genet., 2003, 64(2), 96-103.
106. Ling, S.; Dai, A.; Williams, M.R.; Husband, A.J.; Nestel, P.J.; Komesaroff, P.A.; Sudhir, K. The isoflavone metabolite cistetrahydrodaidzein inhibits ERK-1 activation and proliferation in human vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 2004, 43(5), 622-628.
107. Kim, H.; Lee, M.J.; Kim, J.E.; Park, S.D.; Moon, H.I.; Park, W.H. Genistein suppresses tumor necrosis factor-alpha-induced proliferation via the apoptotic signaling pathway in human aortic smooth muscle cells. J. Agric. Food Chem., 58(3), 2015-2019.
108. Finking, G.; Wohlfrom, M.; Lenz, C.; Wolkenhauer, M.; Eberle, C.; Hanke, H. The phytoestrogens Genistein and Daidzein, and 17 beta-estradiol inhibit development of neointima in aortas from male and female rabbits in vitro after injury. Coron. Artery Dis., 1999, 10(8), 607-615.
109. Pan, W.; Ikeda, K.; Takebe, M.; Yamori, Y. Genistein, daidzein and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. J. Nutr., 2001, 131(4), 1154-1158.
110. Shen, J.; White, M.; Husband, A.J.; Hambly, B.D.; Bao, S. Phytoestrogen derivatives differentially inhibit arterial neointimal proliferation in a mouse model. Eur. J. Pharmacol., 2006, 548(1-3), 123-128.
111. Yu, J.Y.; Lee, J.J.; Lim, Y.; Kim, T.J.; Jin, Y.R.; Sheen, Y.Y.; Yun, Y.P. Genistein inhibits rat aortic smooth muscle cell proliferation through the induction of p27kip1. J. Pharmacol. Sci., 2008, 107(1), 90-98.
112. Liu, S.; Wang, L.; Wang, W.; Lin, J.; Han, J.; Sun, H.; Guo, H.; Sun, R.; Wu, Q. TSC-36/FRP inhibits vascular smooth muscle cell proliferation and migration. Exp. Mol. Pathol., 2006, 80(2), 132-140.
113. Crews, J.K.; Khalil, R.A. Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler. Thromb. Vasc. Biol., 1999, 19(4), 1034-1040.
114. Dean, S.A.; Tan, J.; O'Brien, E.R.; Leenen, F.H. 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol, 2005, 288(3), R759-766.
115. Xu, Y.Y.; Yang, C.; Li, S.N. Effects of genistein on angiotensinconverting enzyme in rats. Life Sci., 2006, 79(9), 828-837.
116. Montenegro, M.F.; Pessa, L.R.; Tanus-Santos, J.E. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin. Eur. J. Pharmacol., 2009, 607(1-3), 173-177.
117. Murphy, J.G.; Khalil, R.A. Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J. Pharmacol. Exp. Ther., 1999, 291(1), 44-52.
118. Ullrich, N.D.; Koschak, A.; MacLeod, K.T. Oestrogen directly inhibits the cardiovascular L-type Ca2+ channel Cav1.2. Biochem. Biophys. Res. Commun., 2007, 361(2), 522-527.
119. Prakash, Y.S.; Togaibayeva, A.A.; Kannan, M.S.; Miller, V.M.; Fitzpatrick, L.A.; Sieck, G.C. Estrogen increases Ca2+ efflux from female porcine coronary arterial smooth muscle. Am J Physiol, 1999, 276(3 Pt 2), H926-934.
120. Speroni, F.; Rebolledo, A.; Salemme, S.; Roldan-Palomo, R.; Rimorini, L.; Anon, M.C.; Spinillo, A.; Tanzi, F.; Milesi, V. Genistein effects on Ca2+ handling in human umbilical artery: inhibition of sarcoplasmic reticulum Ca2+ release and of voltageoperated Ca2+ channels. J. Physiol. Biochem., 2009, 65(2), 113-124.
121. Gould, E.M.; Rembold, C.M.; Murphy, R.A. Genistein, a tyrosine kinase inhibitor, reduces Ca2+ mobilization in swine carotid media. Am. J. Physiol., 1995, 268(6 Pt 1), C1425-1429.
122. Torregrosa, G.; Burguete, M.C.; Perez-Asensio, F.J.; Salom, J.B.; Gil, J.V.; Alborch, E. Pharmacological profile of phytoestrogens in cerebral vessels: in vitro study with rabbit basilar artery. Eur. J. Pharmacol., 2003, 482(1-3), 227-234.
123. Li, H.F.; Zhang, P.; Tian, Z.F.; Qiu, X.Q.; Zhang, Y.F.; Wu, J.X.; Jia, Z.J. Differential mechanisms involved in effects of genistein and 17-beta-estradiol on porcine coronary arteries. Pharmazie, 2006, 61(5), 461-465.
124. Nelson, S.R.; Chien, T.; Di Salvo, J. Genistein sensitivity of calcium transport pathways in serotonin-activated vascular smooth muscle cells. Arch Biochem Biophys, 1997, 345(1), 65-72.
125. Abebe, W.; Agrawal, D.K. Role of tyrosine kinases in norepinephrine-induced contraction of vascular smooth muscle. J. Cardiovasc. Pharmacol., 1995, 26(1), 153-159.
126. Sato, A.; Hattori, Y.; Kanno, M. Effects of genistein and daidzein on enhanced vascular contractile reactivity and Ca2+ sensitivity in cardiomyopathic hamsters. Methods Find Exp. Clin. Pharmacol., 2000, 22(1), 25-30.
127. Nelson, M.T.; Quayle, J.M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am. J. Physiol., 1995, 268(4 Pt 1), C799-822.
128. Han, G.; Yu, X.; Lu, L.; Li, S.; Ma, H.; Zhu, S.; Cui, X.; White, R.E. Estrogen receptor alpha mediates acute potassium channel stimulation in human coronary artery smooth muscle cells. J. Pharmacol. Exp. Ther., 2006, 316(3), 1025-1030.
129. Zhang, H.T.; Wang, Y.; Deng, X.L.; Dong, M.Q.; Zhao, L.M.; Wang, Y.W. Daidzein relaxes rat cerebral basilar artery via activation of large-conductance Ca2+-activated K+ channels in vascular smooth muscle cells. Eur. J. Pharmacol., 630(1-3), 100-106.
130. Nevala, R.; Paukku, K.; Korpela, R.; Vapaatalo, H. Calciumsensitive potassium channel inhibitors antagonize genistein-and daidzein-induced arterial relaxation in vitro. Life Sci., 2001, 69(12), 1407-1417.
131. Speroni, F.; Rebolledo, A.; Salemme, S.; Anon, M.C.; Tanzi, F.; Milesi, V. Genistein inhibits contractile force, intracellular Ca2+ increase and Ca2+ oscillations induced by serotonin in rat aortic smooth muscle. J. Physiol. Biochem., 2007, 63(2), 143-151.
132. Ogata, R.; Kitamura, K.; Ito, Y.; Nakano, H. Inhibitory effects of genistein on ATP-sensitive K+ channels in rabbit portal vein smooth muscle. Br. J. Pharmacol., 1997, 122(7), 1395-1404.
133. Ko, E.A.; Park, W.S.; Son, Y.K.; Kim do, H.; Kim, N.; Kim, H.K.; Choi, T.H.; Jung, I.D.; Park, Y.M.; Han, J. The effect of tyrosine kinase inhibitor genistein on voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. Vascul. Pharmacol., 2009, 50(1-2), 51-56.
134. Nevala, R.; Lassila, M.; Finckenberg, P.; Paukku, K.; Korpela, R.; Vapaatalo, H. Genistein treatment reduces arterial contractions by inhibiting tyrosine kinases in ovariectomized hypertensive rats. Eur. J. Pharmacol., 2002, 452(1), 87-96.
135. Liu, H.; Li, K.; Sperelakis, N. Tyrosine kinase inhibitor, genistein, inhibits macroscopic L-type calcium current in rat portal vein smooth muscle cells. Can. J. Physiol. Pharmacol., 1997, 75(9), 1058-1062.
136. Shimokawa, H.; Takeshita, A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol., 2005, 25(9), 1767-1775.
137. Zhou, Q.; Liao, J.K. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr. Pharm. Des., 2009, 15(27), 3108-3115.
138. Hiroki, J.; Shimokawa, H.; Mukai, Y.; Ichiki, T.; Takeshita, A. Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2005, 326(1), 154-159.
139. Chrissobolis, S.; Budzyn, K.; Marley, P.D.; Sobey, C.G. Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo. Stroke, 2004, 35(9), 2200-2205.
140. Seok, Y.M.; Baek, I.; Kim, Y.H.; Jeong, Y.S.; Lee, I.J.; Shin, D.H.; Hwang, Y.H.; Kim, I.K. Isoflavone attenuates vascular contraction through inhibition of the RhoA/Rho-kinase signaling pathway. J. Pharmacol. Exp. Ther., 2008, 326(3), 991-998.
141. Salamanca, D.A.; Khalil, R.A. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem. Pharmacol., 2005, 70(11), 1537-1547.
142. Kang, J.H.; Niidome, T.; Katayama, Y. Role of estrogenic compounds (diethylstibestrol, 17beta-estradiol, and bisphenol A) in the phosphorylation of substrate by protein kinase Calpha. J. Biochem. Mol. Toxicol., 2009, 23(5), 318-323.
143. Kanashiro, C.A.; Khalil, R.A. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am. J. Physiol. Cell Physiol., 2001, 280(1), C34-45.
144. Park, J.; Chung, S.W.; Kim, S.H.; Kim, T.S. Up-regulation of interleukin-4 production via NF-AT/AP-1 activation in T cells by biochanin A, a phytoestrogen and its metabolites. Toxicol. Appl. Pharmacol., 2006, 212(3), 188-199.
145. Pearson, L.L.; Castle, B.E.; Kehry, M.R. CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptorassociated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways. Int. Immunol., 2001, 13(3), 273-283.
146. Suzuki, T.; Yu, H.P.; Hsieh, Y.C.; Choudhry, M.A.; Bland, K.I.; Chaudry, I.H. Mitogen activated protein kinase (MAPK) mediates non-genomic pathway of estrogen on T cell cytokine production following trauma-hemorrhage. Cytokine., 2008, 42(1), 32-38.
147. Dubey, R.K.; Gillespie, D.G.; Imthurn, B.; Rosselli, M.; Jackson, E.K.; Keller, P.J. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension, 1999, 33(1 Pt 2), 177-182.
148. Kang, O.H.; Jang, H.J.; Chae, H.S.; Oh, Y.C.; Choi, J.G.; Lee, Y.S.; Kim, J.H.; Kim, Y.C.; Sohn, D.H.; Park, H.; Kwon, D.Y. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol. Res., 2009, 59(5), 330-337.
149. Vincent, A.; Ruan, M.; Fitzpatrick, L.A. Gender differences in the effect of genistein on vascular smooth muscle cells: a possible cardioprotective effect? J. Gend. Specif. Med., 2001, 4(1), 28-34.
150. Simoncini, T.; Scorticati, C.; Mannella, P.; Fadiel, A.; Giretti, M.S.; Fu, X.D.; Baldacci, C.; Garibaldi, S.; Caruso, A.; Fornari, L.; Naftolin, F.; Genazzani, A.R. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol. Endocrinol., 2006, 20(8), 1756-1771.
151. Rekhter, M.D. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc. Res., 1999, 41(2), 376-384.
152. Cao, C.; Li, S.; Dai, X.; Chen, Y.; Feng, Z.; Zhao, Y.; Wu, J. Genistein inhibits proliferation and functions of hypertrophic scar fibroblasts. Burns, 2009, 35(1), 89-97.
153. Yuan, W.J.; Jia, F.Y.; Meng, J.Z. Effects of genistein on secretion of extracellular matrix components and transforming growth factor beta in high-glucose-cultured rat mesangial cells. J. Artif. Organs, 2009, 12(4), 242-246.
154. Chen, Z.; Seo, J.Y.; Kim, Y.K.; Lee, S.R.; Kim, K.H.; Cho, K.H.; Eun, H.C.; Chung, J.H. Heat modulation of tropoelastin, fibrillin-1, and matrix metalloproteinase-12 in human skin in vivo. J. Invest. Dermatol., 2005, 124(1), 70-78.
155. Grandas, O.H.; Mountain, D.H.; Kirkpatrick, S.S.; Cassada, D.C.; Stevens, S.L.; Freeman, M.B.; Goldman, M.H. Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure. J. Vasc. Surg., 2009, 49(1), 185-191.
156. Russo, L.A.; Peano, B.J.; Trivedi, S.P.; Cavalcanto, T.D.; Olenchock, B.A.; Caruso, J.A.; Smolock, A.R.; Vishnevsky, O.; Gardner, R.M. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Reprod. Biol. Endocrinol., 2009, 7, 124.
157. Lekontseva, O.; Jiang, Y.; Davidge, S.T. Estrogen replacement increases matrix metalloproteinase contribution to vasoconstriction in a rat model of menopause. J. Hypertens., 2009, 27(8), 1602-1608.
158. Lee, C.S.; Kwon, S.J.; Na, S.Y.; Lim, S.P.; Lee, J.H. Genistein supplementation inhibits atherosclerosis with stabilization of the lesions in hypercholesterolemic rabbits. J. Korean Med. Sci., 2004, 19(5), 656-661.
159. Suh, S.J.; Kim, J.R.; Jin, U.H.; Choi, H.S.; Chang, Y.C.; Lee, Y.C.; Kim, S.H.; Lee, I.S.; Moon, T.C.; Chang, H.W.; Kim, C.H. Deoxypodophyllotoxin, flavolignan, from Anthriscus sylvestris Hoffm. inhibits migration and MMP-9 via MAPK pathways in TNF-alpha-induced HASMC. Vascul. Pharmacol., 2009, 51(1), 13-20.
160. Puli, S.; Lai, J.C.; Bhushan, A. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J. Neurooncol., 2006, 79(2), 135-142.
161. Kousidou, O.C.; Mitropoulou, T.N.; Roussidis, A.E.; Kletsas, D.; Theocharis, A.D.; Karamanos, N.K. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int. J. Oncol., 2005, 26(4), 1101-1109.
162. Huang, X.; Chen, S.; Xu, L.; Liu, Y.; Deb, D.K.; Platanias, L.C.; Bergan, R.C. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res, 2005, 65(8), 3470-3478.
163. Yan, C.; Han, R. Genistein suppresses adhesion-induced protein tyrosine phosphorylation and invasion of B16-BL6 melanoma cells. Cancer Lett., 1998, 129(1), 117-124.
164. Haines, C.; James, A.; Sahota, D.; Chen, Z.Y.; Panesar, N.; Tomlinson, B.; Chow, L.; Benzie, I.; Husband, A. Comparison between phytoestrogens and estradiol in the prevention of atheroma in ovariectomized cholesterol-fed rabbits. Climacteric, 2006, 9(6), 430-436.
165. Nikitina, N.A.; Sobenin, I.A.; Myasoedova, V.A.; Korennaya, V.V.; Mel'nichenko, A.A.; Khalilov, E.M.; Orekhov, A.N. Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull. Exp. Biol. Med., 2006, 141(6), 712-715.
166. Fuchs, D.; de Pascual-Teresa, S.; Rimbach, G.; Virgili, F.; Ambra, R.; Turner, R.; Daniel, H.; Wenzel, U. Proteome analysis for identification of target proteins of genistein in primary human endothelial cells stressed with oxidized LDL or homocysteine. Eur. J. Nutr., 2005, 44(2), 95-104.
167. Honore, E.K.; Williams, J.K.; Anthony, M.S.; Clarkson, T.B. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil. Steril., 1997, 67(1), 148-154.
168. Zhao, H.; Li, C.; Cao, J.G.; Xiang, H.L.; Yang, H.Z.; You, J.L.; Li, C.L.; Fu, X.H. 7-Difluoromethyl-5,4'-dimethoxygenistein, a novel genistein derivative, has therapeutic effects on atherosclerosis in a rabbit model. J. Cardiovasc. Pharmacol., 2009, 54(5), 412-420.
169. Wang, Z.; Zou, J.; Cao, K.; Hsieh, T.C.; Huang, Y.; Wu, J.M. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int. J. Mol. Med., 2005, 16(4), 533-540.
170. Zou, J.; Huang, Y.; Cao, K.; Yang, G.; Yin, H.; Len, J.; Hsieh, T.C.; Wu, J.M. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci., 2000, 68(2), 153-163.
171. Olas, B.; Wachowicz, B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. Platelets, 2005, 16(5), 251-260.
172. Brito, P.; Almeida, L.M.; Dinis, T.C. The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against LDL oxidation. Free Radic. Res., 2002, 36(6), 621-631.
173. Nakano, Y.; Oshima, T.; Ozono, R.; Ueda, A.; Oue, Y.; Matsuura, H.; Sanada, M.; Ohama, K.; Chayama, K.; Kambe, M. Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca(2+) influx and raising cyclic adenosine monophosphate. Cardiovasc. Res., 2002, 53(3), 634-641.
174. Moro, L.; Reineri, S.; Piranda, D.; Pietrapiana, D.; Lova, P.; Bertoni, A.; Graziani, A.; Defilippi, P.; Canobbio, I.; Torti, M.; Sinigaglia, F. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood, 2005, 105(1), 115-121.
175. Wilcox, J.N.; Blumenthal, B.F. Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. J. Nutr., 1995, 125(3 Suppl), 631S-638S.
176. Kondo, K.; Suzuki, Y.; Ikeda, Y.; Umemura, K. Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation. Eur. J. Pharmacol., 2002, 455(1), 53-57.
177. Schoene, N.W.; Guidry, C.A. Dietary soy isoflavones inhibit activation of rat platelets. J. Nutr. Biochem., 1999, 10(7), 421-426.
178. Polini, N.; Rauschemberger, M.B.; Mendiberri, J.; Selles, J.; Massheimer, V. Effect of genistein and raloxifene on vascular dependent platelet aggregation. Mol. Cell Endocrinol., 2007, 267(1-2), 55-62.
179. Guerrero, J.A.; Lozano, M.L.; Castillo, J.; Benavente-Garcia, O.; Vicente, V.; Rivera, J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J. Thromb Haemost., 2005, 3(2), 369-376.
180. Stef, G.; Csiszar, A.; Lerea, K.; Ungvari, Z.; Veress, G. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J. Cardiovasc. Pharmacol., 2006, 48(2), 1-5.
181. Fait, T.; Vrablik, M.; Zizka, Z.; Trnkova, B.; Masata, J.; Zivny, J. [Effect of early onset of transdermal and oral estrogen therapy on the lipid profile: a prospective study with cross-over design]. Ceska Gynekol, 2006, 71(3), 226-230.
182. Guo, Y.; Wu, G.; Su, X.; Yang, H.; Zhang, J. Antiobesity action of a daidzein derivative on male obese mice induced by a high-fat diet. Nutr Res., 2009, 29(9), 656-663.
183. Kapiotis, S.; Hermann, M.; Held, I.; Seelos, C.; Ehringer, H.; Gmeiner, B.M. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler. Thromb Vasc. Biol., 1997, 17(11), 2868-2874.
184. Bassett, C.M.; Rodriguez-Leyva, D.; Pierce, G.N. Experimental and clinical research findings on the cardiovascular benefits of consuming flaxseed. Appl. Physiol. Nutr. Metab., 2009, 34(5), 965-974.
185. Fukumitsu, S.; Aida, K.; Ueno, N.; Ozawa, S.; Takahashi, Y.; Kobori, M. Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. Br. J. Nutr., 2008, 100(3), 669-676.
186. Relic, B.; Zeddou, M.; Desoroux, A.; Beguin, Y.; de Seny, D.; Malaise, M.G. Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts. Lab. Invest., 2009, 89(7), 811-822.
187. Inoue, M.; Ishida, T.; Yasuda, T.; Toh, R.; Hara, T.; Cangara, H.M.; Rikitake, Y.; Taira, K.; Sun, L.; Kundu, R.K.; Quertermous, T.; Hirata, K. Endothelial cell-selective adhesion molecule modulates atherosclerosis through plaque angiogenesis and monocyte-endothelial interaction. Microvasc. Res., 80(2), 179-187.
188. Aberdeen, G.W.; Wiegand, S.J.; Bonagura, T.W., Jr.; Pepe, G.J.; Albrecht, E.D. Vascular endothelial growth factor mediates the estrogen-induced breakdown of tight junctions between and increase in proliferation of microvessel endothelial cells in the baboon endometrium. Endocrinology, 2008, 149(12), 6076-6083.
189. Groten, T.; Pierce, A.A.; Huen, A.C.; Schnaper, H.W. 17 betaestradiol transiently disrupts adherens junctions in endothelial cells. FASEB J., 2005, 19(10), 1368-1370.
190. Huh, J.E.; Kwon, N.H.; Baek, Y.H.; Lee, J.D.; Choi, D.Y.; Jingushi, S.; Kim, K.I.; Park, D.S. Formononetin promotes early fracture healing through stimulating angiogenesis by up-regulating VEGFR-2/Flk-1 in a rat fracture model. Int. Immunopharmacol., 2009, 9(12), 1357-1365.
191. Sasamura, H.; Takahashi, A.; Yuan, J.; Kitamura, H.; Masumori, N.; Miyao, N.; Itoh, N.; Tsukamoto, T. Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Urology, 2004, 64(2), 389-393.
192. Ambra, R.; Rimbach, G.; de Pascual Teresa, S.; Fuchs, D.; Wenzel, U.; Daniel, H.; Virgili, F. Genistein affects the expression of genes involved in blood pressure regulation and angiogenesis in primary human endothelial cells. Nutr. Metab. Cardiovasc. Dis., 2006, 16(1), 35-43.
193. Piao, M.; Mori, D.; Satoh, T.; Sugita, Y.; Tokunaga, O. Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium, 2006, 13(4), 249-266.
194. Su, S.J.; Yeh, T.M.; Chuang, W.J.; Ho, C.L.; Chang, K.L.; Cheng, H.L.; Liu, H.S.; Hsu, P.Y.; Chow, N.H. The novel targets for antiangiogenesis of genistein on human cancer cells. Biochem. Pharmacol., 2005, 69(2), 307-318.
195. Bergman Jungestrom, M.; Thompson, L.U.; Dabrosin, C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin. Cancer Res., 2007, 13(3), 1061-1067.
196. Gao, H.; Liang, M.; Bergdahl, A.; Hamren, A.; Lindholm, M.W.; Dahlman-Wright, K.; Nilsson, B.O. Estrogen attenuates vascular expression of inflammation associated genes and adhesion of monocytes to endothelial cells. Inflamm. Res., 2006, 55(8), 349-353.
197. Geraldes, P.; Gagnon, S.; Hadjadj, S.; Merhi, Y.; Sirois, M.G.; Cloutier, I.; Tanguay, J.F. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovasc. Res., 2006, 71(3), 566-573.
198. Xu, Y.; Arenas, I.A.; Armstrong, S.J.; Plahta, W.C.; Xu, H.; Davidge, S.T. Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing tumor necrosis factor-alpha. Cardiovasc. Res., 2006, 69(4), 836-844.
199. Dharmappa, K.K.; Mohamed, R.; Shivaprasad, H.V.; Vishwanath, B.S. Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation. Inflammopharmacology, 18(1), 25-31.
200. Trompezinski, S.; Denis, A.; Schmitt, D.; Viac, J. Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal human keratinocytes stimulated with the proinflammatory cytokine TNFalpha. Arch. Dermatol. Res., 2003, 295(3), 112-116.
201. Gottstein, N.; Ewins, B.A.; Eccleston, C.; Hubbard, G.P.; Kavanagh, I.C.; Minihane, A.M.; Weinberg, P.D.; Rimbach, G. Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function. Br. J. Nutr., 2003, 89(5), 607-616.
202. Lee, Y.W.; Lee, W.H. Protective effects of genistein on proinflammatory pathways in human brain microvascular endothelial cells. J. Nutr. Biochem., 2008, 19(12), 819-825.
203. van Hinsbergh, V.W.; Vermeer, M.; Koolwijk, P.; Grimbergen, J.; Kooistra, T. Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells. Blood, 1994, 84(9), 2984-2991.
204. Schrepfer, S.; Deuse, T.; Schafer, H.; Koch-Nolte, F.; Braendle, W.; Reichenspurner, H. The phytoestrogen biochaninA weakens acute cardiac allograft rejection without affecting the reproductive system. Transpl. Immunol., 2005, 15(1), 45-53.
205. Khanna, D.; Sethi, G.; Ahn, K.S.; Pandey, M.K.; Kunnumakkara, A.B.; Sung, B.; Aggarwal, A.; Aggarwal, B.B. Natural products as a gold mine for arthritis treatment. Curr. Opin. Pharmacol., 2007, 7(3), 344-351.
206. Nichols, J.A.; Katiyar, S.K. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res, 302(2), 71-83.
207. Kalhan, R.; Smith, L.J.; Nlend, M.C.; Nair, A.; Hixon, J.L.; Sporn, P.H. A mechanism of benefit of soy genistein in asthma: inhibition of eosinophil p38-dependent leukotriene synthesis. Clin. Exp. Allergy, 2008, 38(1), 103-112.
208. Cignarella, A.; Minici, C.; Bolego, C.; Pinna, C.; Sanvito, P.; Gaion, R.M.; Puglisi, L. Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. Nutr. Metab. Cardiovasc. Dis., 2006, 16(5), 322-329.
209. Wing, L.Y.; Chen, Y.C.; Shih, Y.Y.; Cheng, J.C.; Lin, Y.J.; Jiang, M.J. Effects of oral estrogen on aortic ROS-generating and-scavenging enzymes and atherosclerosis in apoE-deficient mice. Exp. Biol. Med. (Maywood), 2009, 234(9), 1037-1046.
210. Patel, R.P.; Crawford, J.; Boersma, B.; Barnes, S.; Darley-Usmar, V.M. Antioxidant properties of phytoestrogens. J. Med. Food, 1999, 2(3-4), 163-166.
211. Exner, M.; Hermann, M.; Hofbauer, R.; Kapiotis, S.; Quehenberger, P.; Speiser, W.; Held, I.; Gmeiner, B.M. Genistein prevents the glucose autoxidation mediated atherogenic modification of low density lipoprotein. Free Radic. Res., 2001, 34(1), 101-112.
212. Xu, S.Z.; Zhong, W.; Ghavideldarestani, M.; Saurabh, R.; Lindow, S.W.; Atkin, S.L. Multiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury. Free Radic. Biol. Med., 2009, 47(2), 167-175.
213. Hwang, J.; Hodis, H.N.; Sevanian, A. Soy and alfalfa phytoestrogen extracts become potent low-density lipoprotein antioxidants in the presence of acerola cherry extract. J. Agric Food Chem., 2001, 49(1), 308-314.
214. Zhang, P.; Li, H.F.; Tian, Z.F.; Qiu, X.Q.; Wu, J.X.; Jia, Z.J. Effects of phytoestrogens and 17beta-estradiol on vasoconstriction elicited by reactive oxygen species. Pharmazie., 2007, 62(5), 378-381.
215. Mizutani, K.; Ikeda, K.; Nishikata, T.; Yamori, Y. Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J. Hypertens., 2000, 18(12), 1833-1840.
216. Chung, J.E.; Kim, S.Y.; Jo, H.H.; Hwang, S.J.; Chae, B.; Kwon, D.J.; Lew, Y.O.; Lim, Y.T.; Kim, J.H.; Kim, E.J.; Kim, M.R. Antioxidant effects of equol on bovine aortic endothelial cells. Biochem. Biophys. Res. Commun., 2008, 375(3), 420-424.
217. Labinskyy, N.; Csiszar, A.; Orosz, Z.; Smith, K.; Rivera, A.; Buffenstein, R.; Ungvari, Z. Comparison of endothelial function, O2-* and H2O2 production, and vascular oxidative stress resistance between the longest-living rodent, the naked mole rat, and mice. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(6), H2698-2704.
218. Clarkson, T.B.; Anthony, M.S.; Morgan, T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J. Clin. Endocrinol. Metab., 2001, 86(1), 41-47.
219. Cornwell, T.; Cohick, W.; Raskin, I. Dietary phytoestrogens and health. Phytochemistry, 2004, 65(8), 995-1016.
220. Mazur, W. Phytoestrogen content in foods. Baillieres Clin. Endocrinol. Metab., 1998, 12(4), 729-742.
221. Chan, Y.H.; Lau, K.K.; Yiu, K.H.; Li, S.W.; Chan, H.T.; Tam, S.; Shu, X.O.; Lau, C.P.; Tse, H.F. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr, 2007, 86(4), 938-945.
222. Squadrito, F.; Altavilla, D.; Crisafulli, A.; Saitta, A.; Cucinotta, D.; Morabito, N.; D'Anna, R.; Corrado, F.; Ruggeri, P.; Frisina, N.; Squadrito, G. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am. J. Med., 2003, 114(6), 470-476.
223. Cruz, M.N.; Agewall, S.; Schenck-Gustafsson, K.; Kublickiene, K. Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. Atherosclerosis, 2008, 196(1), 49-58.
224. Chin-Dusting, J.P.; Boak, L.; Husband, A.; Nestel, P.J. The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism. Atherosclerosis, 2004, 176(1), 45-48.
225. Katz, D.L.; Evans, M.A.; Njike, V.Y.; Hoxley, M.L.; Nawaz, H.; Comerford, B.P.; Sarrel, P.M. Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric., 2007, 10(6), 500-507.
226. Hallund, J.; Tetens, I.; Bugel, S.; Tholstrup, T.; Ferrari, M.; Teerlink, T.; Kjaer, A.; Wiinberg, N. Daily consumption for six weeks of a lignan complex isolated from flaxseed does not affect endothelial function in healthy postmenopausal women. J. Nutr., 2006, 136(9), 2314-2318.
227. Penotti, M.; Fabio, E.; Modena, A.B.; Rinaldi, M.; Omodei, U.; Vigano, P. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril., 2003, 79(5), 1112-1117.
228. Beavers, D.P.; Beavers, K.M.; Miller, M.; Stamey, J.; Messina, M.J. Exposure to isoflavone-containing soy products and endothelial function: A Bayesian meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis.
229. Li, S.H.; Liu, X.X.; Bai, Y.Y.; Wang, X.J.; Sun, K.; Chen, J.Z.; Hui, R.T. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am. J. Clin. Nutr., 91(2), 480-486.
230. Nagata, C.; Takatsuka, N.; Kurisu, Y.; Shimizu, H. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. J. Nutr., 1998, 128(2), 209-213.
231. Bairey Merz, C.N.; Johnson, B.D.; Braunstein, G.D.; Pepine, C.J.; Reis, S.E.; Paul-Labrador, M.; Hale, G.; Sharaf, B.L.; Bittner, V.; Sopko, G.; Kelsey, S.F. Phytoestrogens and lipoproteins in women. J. Clin. Endocrinol. Metab., 2006, 91(6), 2209-2213.
232. Simons, L.A.; von Konigsmark, M.; Simons, J.; Celermajer, D.S. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am. J. Cardiol., 2000, 85(11), 1297-1301.
233. Crouse, J.R., 3rd; Morgan, T.; Terry, J.G.; Ellis, J.; Vitolins, M.; Burke, G.L. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch. Intern. Med., 1999, 159(17), 2070-2076.
234. Okamura, S.; Sawada, Y.; Satoh, T.; Sakamoto, H.; Saito, Y.; Sumino, H.; Takizawa, T.; Kogure, T.; Chaichantipyuth, C.; Higuchi, Y.; Ishikawa, T.; Sakamaki, T. Pueraria mirifica phytoestrogens improve dyslipidemia in postmenopausal women probably by activating estrogen receptor subtypes. Tohoku J. Exp. Med., 2008, 216(4), 341-351.
235. Blum, A.; Lang, N.; Vigder, F.; Israeli, P.; Gumanovsky, M.; Lupovitz, S.; Elgazi, A.; Peleg, A.; Ben-Ami, M. Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. Clin. Invest. Med., 2003, 26(1), 20-26.
236. Tormala, R.M.; Nikander, E.; Tiitinen, A.; Vaisanen-Tommiska, M.; Ylikorkala, O.; Mikkola, T.S. Serum cholesterol efflux potential in postmenopausal women treated with isolated isoflavones. Menopause, 2006, 13(1), 96-101.
237. Hallund, J.; Ravn-Haren, G.; Bugel, S.; Tholstrup, T.; Tetens, I. A lignan complex isolated from flaxseed does not affect plasma lipid concentrations or antioxidant capacity in healthy postmenopausal women. J. Nutr., 2006, 136(1), 112-116.
238. Rios, D.R.; Rodrigues, E.T.; Cardoso, A.P.; Montes, M.B.; Franceschini, S.A.; Toloi, M.R. Lack of effects of isoflavones on the lipid profile of Brazilian postmenopausal women. Nutrition, 2008, 24(11-12), 1153-1158.
239. Pellegrini, N.; Valtuena, S.; Ardigo, D.; Brighenti, F.; Franzini, L.; Del Rio, D.; Scazzina, F.; Piatti, P.M.; Zavaroni, I. Intake of the plant lignans matairesinol, secoisolariciresinol, pinoresinol, and lariciresinol in relation to vascular inflammation and endothelial dysfunction in middle age-elderly men and post-menopausal women living in Northern Italy. Nutr. Metab. Cardiovasc. Dis., 20(1), 64-71.
240. Colacurci, N.; Chiantera, A.; Fornaro, F.; de Novellis, V.; Manzella, D.; Arciello, A.; Chiantera, V.; Improta, L.; Paolisso, G. Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause, 2005, 12(3), 299-307.
241. Chen, C.Y.; Bakhiet, R.M.; Hart, V.; Holtzman, G. Isoflavones improve plasma homocysteine status and antioxidant defense system in healthy young men at rest but do not ameliorate oxidative stress induced by 80% VO2pk exercise. Ann. Nutr. Metab., 2005, 49(1), 33-41.
242. Vafeiadou, K.; Hall, W.L.; Williams, C.M. Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women. Proc. Nutr. Soc., 2006, 65(1), 106-115.
243. Hallund, J.; Tetens, I.; Bugel, S.; Tholstrup, T.; Bruun, J.M. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr. Metab. Cardiovasc. Dis., 2008, 18(7), 497-502.
244. Mink, P.J.; Scrafford, C.G.; Barraj, L.M.; Harnack, L.; Hong, C.P.; Nettleton, J.A.; Jacobs, D.R., Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am. J. Clin. Nutr., 2007, 85(3), 895-909.
245. Kreijkamp-Kaspers, S.; Kok, L.; Bots, M.L.; Grobbee, D.E.; van der Schouw, Y.T. Dietary phytoestrogens and vascular function in postmenopausal women: a cross-sectional study. J. Hypertens, 2004, 22(7), 1381-1388.
246. Teede, H.J.; McGrath, B.P.; De Silva, L.; Cehun, M.; Fassoulakis, A.; Nestel, P.J. Isoflavones reduce arterial stiffness: a placebocontrolled study in men and postmenopausal women. Arterioscler. Thromb. Vasc. Biol., 2003, 23(6), 1066-1071.